



## **Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPEs 2024**

Sep 25, 2024

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowth210 clinical trial has been accepted for presentation at the [13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society](#), or APPEs 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowth210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3<sup>rd</sup> by [Professor Paul Hofman, MD](#), Liggins Institute, University of Auckland, Auckland, New Zealand.

**Abstract Presentation: Thursday, October 3<sup>rd</sup> – Oral Session: Growth & Puberty – 2:30PM Local Time**

- Abstract entitled, *Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowth210 Trial* (Paul Hofman, MD, et al)

### **About Lumos Pharma**

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma's lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~\$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.